The elevated odds of adverse outcomes in pregnancies occurring years before an SLE diagnosis aligns with a broader body of evidence indicating that the pathogenic processes underlying lupus begin long before patients meet classification criteria. Autoantibodies such as antinuclear antibodies, anti-double stranded DNA, and antiphospholipid antibodies can circulate for years, and in some cases more than a decade, before the emergence of characteristic clinical symptoms. During this preclinical window, low-grade inflammation, endothelial dysfunction, and immune complex formation may already be operative, and each of these mechanisms has plausible links to the placental and vascular pathology that underlies preeclampsia, fetal growth restriction, and pregnancy loss. The persistence of elevated risk even in pregnancies occurring more than five years before diagnosis, as seen in this cohort, suggests that subclinical immune dysregulation is not merely a transient precursor but a sustained biological state with real consequences for reproductive health.

Placental pathology offers one framework for understanding these associations. In established SLE, adverse pregnancy outcomes are frequently attributed to a combination of placental insufficiency, antiphospholipid antibody-mediated thrombosis, and complement activation at the maternal-fetal interface. Antiphospholipid antibodies in particular are known to bind trophoblast surfaces, interfere with normal placentation, and trigger complement-mediated inflammation that can culminate in early pregnancy loss or later-onset preeclampsia. If these antibodies or related immune disturbances are present during the preclinical phase of lupus, they could plausibly exert similar effects before any diagnosis is made. The study’s inclusion of antiphospholipid antibody status among the measured immunologic variables reflects this mechanistic reasoning, although the retrospective design means that the timing of antibody acquisition relative to individual pregnancies could not always be established with certainty.

The demographic composition of the cohort deserves attention when interpreting the findings. With more than four-fifths of participants self-identifying as Black and nearly a third residing in areas of high social vulnerability, the study captures a population that bears a disproportionate burden of both lupus incidence and poor pregnancy outcomes in the United States. Black women develop lupus at younger ages, experience more aggressive disease courses, and face higher rates of preeclampsia, preterm birth, and fetal demise compared with white women, even after accounting for socioeconomic factors. Structural determinants of health, including differential access to prenatal care, exposure to chronic stress, and environmental exposures, may compound the immunologic risks documented here. The use of an area-based social vulnerability measure in the analysis acknowledges this reality, and the fact that elevated pre-diagnosis risk persisted after adjustment suggests that the association is not fully explained by socioeconomic disadvantage alone, although residual confounding cannot be excluded in an observational design of this kind.

The methodological choice to use generalized estimating equations is well suited to this dataset, given that many participants contributed multiple pregnancies and outcomes within a single individual are correlated. By accounting for this within-person clustering, the analysis avoids the inflated precision that would result from treating repeated pregnancies as independent observations. The comparison strategy, anchoring risk estimates to ANA-positive controls rather than only ANA-negative controls, is also informative, because it isolates the contribution of evolving disease from the contribution of autoantibody positivity per se. The finding that ANA-positive and ANA-negative controls did not differ meaningfully in adverse outcome rates strengthens the conclusion that the excess risk among pre-diagnosis pregnancies stems from the underlying disease process rather than from serologic status alone.

Several limitations temper the interpretation of these results. The single-center design, drawing on a cohort established at one academic medical center, may limit generalizability to populations with different demographic and clinical profiles. The retrospective ascertainment of pregnancy histories, gathered through in-person interviews supplemented by electronic medical record review, introduces the possibility of recall bias, particularly for outcomes such as early spontaneous abortion that may not have been medically documented. The timing of autoantibody measurement relative to individual pregnancies was not standardized, meaning that some participants classified as ANA-positive controls may have seroconverted after their pregnancies, while some pre-diagnosis pregnancies may have occurred before any detectable autoimmunity. Classification of pregnancies by their temporal relationship to diagnosis also depends on the accuracy of the recorded diagnosis date, which itself may lag the true clinical onset of disease. Despite these constraints, the internal consistency of the dose-response-like pattern across the spectrum lends credibility to the central finding.

From a clinical standpoint, the results support the idea that pregnancy may serve as a sentinel opportunity for identifying women at risk of developing lupus. Pregnant women routinely engage with the health system through prenatal visits, laboratory testing, and ultrasound monitoring, creating multiple touchpoints where subtle signs of emerging autoimmunity could be recognized. Women who experience unexplained adverse pregnancy outcomes, particularly recurrent losses, severe or early-onset preeclampsia, or unexplained fetal growth restriction, are already sometimes evaluated for antiphospholipid syndrome and other rheumatologic conditions. The present findings suggest that such evaluations may be worthwhile even when the adverse outcome occurred years before any rheumatologic symptoms appear, and that a history of adverse pregnancy outcomes could be considered a potential marker within the preclinical lupus spectrum warranting longitudinal follow-up.

For rheumatologists and obstetricians caring for women with known SLE, the markedly elevated odds of adverse outcomes after diagnosis, roughly threefold in this cohort, reinforce established guidance that pregnancies in lupus patients should be planned when disease is quiescent and managed with coordinated multidisciplinary care. Hydroxychloroquine, low-dose aspirin, and careful monitoring of renal function and serologic activity are among the interventions with evidence for improving outcomes in this population. The lower median number of pregnancies observed among women after diagnosis may reflect both counseling about contraceptive choices and disease-related subfertility or pregnancy loss, underscoring how a lupus diagnosis reshapes reproductive trajectories.

Future research directions follow naturally from these findings. Prospective studies that measure autoantibodies and inflammatory markers serially before and during pregnancy could clarify whether specific immunologic signatures predict adverse outcomes within the preclinical window. Mechanistic work examining complement activation, type I interferon signaling, and placental pathology in pre-diagnosis pregnancies could illuminate the biological pathways involved. Additionally, investigating whether early intervention during the pre-SLE phase, such as hydroxychloroquine initiation in ANA-positive individuals with concerning features, could mitigate pregnancy risk represents a compelling question for clinical trials. Finally, replicating these results in more diverse cohorts and in centers serving different populations would establish whether the pre-diagnosis risk gradient is a general feature of lupus natural history or is modified by demographic and social context.

In sum, this study adds to a growing recognition that systemic lupus erythematosus is not a disease with a discrete onset but rather the culmination of a prolonged period of immune dysregulation with clinically meaningful consequences. The demonstration that pregnancy outcomes are compromised years before diagnosis, while isolated autoantibody positivity remains benign, refines the concept of the pre-SLE state and offers a practical framework for risk stratification. For women of childbearing age with lupus in their families, unexplained adverse pregnancy outcomes, or evolving autoimmunity, these findings argue for heightened vigilance and for viewing the reproductive years as both a window of vulnerability and an opportunity for earlier detection.

Subject of Research: Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus

Article Title: Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus

Article References: English, J. A., Wolf, B. J., & Kamen, D. L. (2026). Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus. Frontiers in Lupus, 4, Article 1806496. https://doi.org/10.3389/flupu.2026.1806496

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1806496

Keywords: lupus, pregnancy, autoimmunity, ANA, preeclampsia, preterm birth, reproductive health, rheumatology, Adverse, outcome, associations, women